HPV vaccine: what does the evidence show?
The HPV vaccine is designed to reduce infections with human papillomavirus types associated with several cancers. This page separates established benefits, common side effects and continuing safety surveillance.
What is HPV?
Human papillomavirus is a common group of viruses. Many infections cause no lasting harm, but some HPV types are associated with cervical, anal, penile, vulval, vaginal and some mouth and throat cancers. Other types can cause genital warts.
What does the vaccine do?
The vaccine trains the immune system to recognise selected HPV types before infection. It is preventive rather than a treatment for an HPV infection someone already has.
What side effects are commonly reported?
The NHS lists short-lived effects such as pain or swelling at the injection site, headache, fever, dizziness, nausea and tiredness. Severe allergic reactions can occur but are described as very rare.
What about longer-term safety claims?
WHO's vaccine-safety reviews have examined concerns including autoimmune, neurological and thromboembolic conditions. Large population studies and post-marketing surveillance reviewed by WHO have not established the broad causal associations sometimes alleged online.
Primary sources
Current UK patient information on eligibility, effectiveness and side effects.
Global Advisory Committee on Vaccine Safety reviews and evidence summaries.